STERIS plc: insider trades · United States · SEC (Form 4)

About STERIS plc

STERIS plc (NYSE: STE) is a health-care and industrial technology company headquartered operationally in Mentor, Ohio, United States, with the parent company domiciled in Ireland and listed on the NYSE. From an equity-analysis perspective, STERIS is best understood as a global infection-prevention and sterilization platform serving hospitals, ambulatory surgery centers, GI clinics, laboratories, pharmaceutical manufacturers, and medical-device companies. The company’s roots go back to 1985, when it was founded in Mentor, Ohio as Innovative Medical Technologies. Over time, STERIS expanded through a series of acquisitions and portfolio shifts, building a more diversified business across capital equipment, consumables, field services, and contract sterilization. Today, the business is organized into three reportable segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. Healthcare offers a broad mix of infection-prevention products, surgical equipment, GI solutions, and service offerings that support operating rooms and sterile-processing environments. AST provides contract sterilization and microbial reduction services for medical-device, pharmaceutical, consumer, and industrial customers, backed by a global network of sterilization and laboratory facilities. Life Sciences focuses on contamination control for research and manufacturing environments, supplying equipment, formulated cleaning chemistries, consumables, and service solutions designed to create and maintain sterile conditions. The portfolio is attractive because it combines capital equipment with recurring consumables and service revenue, which generally supports a more durable revenue profile than a pure equipment model. Competitively, STERIS benefits from scale, technical expertise, and high regulatory barriers in the infection-control and sterilization markets. These are markets where customer validation cycles are long, quality requirements are strict, and switching costs can be meaningful. The company serves customers in more than 60 countries and has an established international footprint. For the fiscal year ended March 31, 2025, STERIS reported revenue of $5.46 billion, with the bulk of sales generated by Healthcare, AST, and Life Sciences. A major portfolio event was the divestiture of the Dental segment, which sharpened the company’s strategic focus on higher-priority, higher-quality growth areas. Recent developments remain important for investors monitoring Form 4 insider activity and broader governance signals. On May 11, 2026, STERIS reported fiscal 2026 fourth-quarter and full-year results, highlighting 9% full-year revenue growth from continuing operations and a 7% constant-currency organic revenue increase. The board also approved a new $1 billion share repurchase program, replacing the prior authorization. That combination of growth and capital returns underscores a company that continues to generate strong cash flow while investing in its core franchises. For francophone investors, STERIS is a NYSE-listed U.S. company with defensive end-markets, international diversification, and a clear strategic emphasis on infection prevention, sterilization, and procedural workflow solutions.